Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04981704 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants
A Phase 1 study, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT04981704 is a Phase 1 study that has completed, run by Spectrum Pharmaceuticals. The registered enrollment target is 74 participants.
The verdict
NCT04981704, a Phase 1 study, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effect of multiple-doses of itraconazole, phenytoin and paroxetine on the single-dose pharmacokinetics (PK) of poziotinib in healthy adult participants.
Interventions
- DRUG Itraconazole
- DRUG Paroxetine
- DRUG Phenytoin
- DRUG Poziotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2021-04-08 |
| Est. Completion | 2021-08-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04981704
The ClinicalTrials.gov registry entry for NCT04981704 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Itraconazole is the first listed.
NCT04981704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04981704 about?
NCT04981704 is a clinical study titled "A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants". The purpose of the study is to evaluate the effect of multiple-doses of itraconazole, phenytoin and paroxetine on the single-dose pharmacokinetics (PK) of poziotinib in healthy adult participants.
What is the current status of trial NCT04981704?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2021-04-08. Estimated completion is 2021-08-17.
What interventions are being tested in trial NCT04981704?
The interventions under investigation include: Itraconazole (DRUG), Paroxetine (DRUG), Phenytoin (DRUG), Poziotinib (DRUG).
Who is sponsoring clinical trial NCT04981704?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.